SEARCH

SEARCH BY CITATION

References

  • 1
    Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82: 500504.
  • 2
    Ludlam CA, Pasi KJ, Bolton-Maggs P et al. A framework for genetic service provision for haemophilia and other inherited bleeding disorders. Haemophilia 2005; 11: 145163.
  • 3
    McIntyre L. Pre-implantation diagnosis. STEER: Succinct Timely Eval Evid Rev 2001; 1: 19.
  • 4
    Michaelides K, Tuddenham EG, Turner C, Lavender B, Lavery SA. Live birth following the first mutation specific pre-implantation genetic diagnosis for haemophilia A. Thromb Haemost 2006; 95: 373379.
  • 5
    Human Fertilisation and Embryology Authority. HFEA Guide to Infertility and Directory of Clinics 2005/06. London: Human Fertilisation and Embryology Authority, 2006.
  • 6
    Department of Health UK. Preimplantation Genetic Diagnosis (PGD) – Guiding Principles for Commissioners of NHS Services. UK: Department of Health UK, 2002.
  • 7
    Thornhill AR, De Die-Smulders CE, Geraedts JP et al. ESHRE PGD Consortium ‘Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)’. Hum Reprod 2005; 20: 3548.
  • 8
    Firth HV, Boyd PA, Chamberlain PF, MacKenzie IZ, Morriss-Kay GM, Huson SM. Analysis of limb reduction defects in babies exposed to chorionic villus sampling. Lancet 1994; 343: 10691071.
  • 9
    Nicolaides K, Brizot ML, Patel F, Snijders R. Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10–13 weeks’ gestation. Lancet 1994; 344: 435439.
  • 10
    Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986; 1: 12871293.
  • 11
    Wilson RD, Farquharson DF, Wittmann BK, Shaw D. Cordocentesis: overall pregnancy loss rate as important as procedure loss rate. Fetal Diagn Ther 1994; 9: 142148.
  • 12
    Forestier F, Daffos F, Rainaut M, Sole Y, Amiral J. Vitamin K dependent proteins in fetal hemostasis at mid trimester of pregnancy. Thromb Haemost 1985; 53: 401403.
  • 13
    Forestier F, Daffos F, Galacteros F, Bardakjian J, Rainaut M, Beuzard Y. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986; 20: 342346.
  • 14
    Royal College of Obstetricians and Gynaecologists. Amniocentesis and Chorionic Villus Sampling. Guideline No. 8. London: RCOG Press, 2005.
  • 15
    Stephens JD, Sherman S. Determination of fetal sex by ultrasound. N Engl J Med 1983; 309: 984.
  • 16
    Plattner G, Renner W, Went J, Beaudette L, Viau G. Fetal sex determination by ultrasound scan in the second and third trimesters. Obstet Gynecol 1983; 61: 454458.
  • 17
    Birnholz JC. Determination of fetal sex. N Engl J Med 1983; 309: 942944.
  • 18
    Natsuyama E. Sonographic determination of fetal sex from twelve weeks of gestation. Am J Obstet Gynecol 1984; 149: 748757.
  • 19
    Elejalde BR, De Elejalde MM, Heitman T. Visualization of the fetal genitalia by ultrasonography: a review of the literature and analysis of its accuracy and ethical implications. J Ultrasound Med 1985; 4: 633639.
  • 20
    Ammini AC, Sabherwal U, Mukhopadhyay C, Vijayaraghavan M, Pandey J. Morphogenesis of the human external male genitalia. Pediatr Surg Int 1997; 12: 401406.
  • 21
    Whitlow BJ, Lazanakis MS, Economides DL. The sonographic identification of fetal gender from 11 to 14 weeks of gestation. Ultrasound Obstet Gynecol 1999; 13: 301304.
  • 22
    Efrat Z, Akinfenwa OO, Nicolaides KH. First-trimester determination of fetal gender by ultrasound. Ultrasound Obstet Gynecol 1999; 13: 305307.
  • 23
    Costa JM, Benachi A, Gautier E, Jouannic JM, Ernault P, Dumez Y. First-trimester fetal sex determination in maternal serum using real-time PCR. Prenat Diagn 2001; 21: 10701074.
  • 24
    Honda H, Miharu N, Ohashi Y et al. Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum. Hum Genet 2002; 110: 7579.
  • 25
    Hromadnikova I, Houbova B, Hridelova D et al. Replicate real-time PCR testing of DNA in maternal plasma increases the sensitivity of non-invasive fetal sex determination. Prenat Diagn 2003; 23: 235238.
  • 26
    Chi C, Hyett JA, Finning KM, Lee CA, Kadir RA. Non-invasive first trimester determination of fetal gender: a new approach for prenatal diagnosis of haemophilia. BJOG 2006; 113: 239242.
  • 27
    Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991; 98: 909918.
  • 28
    Kadir RA, Economides DL, Braithwaite J, Goldman E, Lee CA. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol 1997; 104: 803810.
  • 29
    United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 123.
  • 30
    Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol 1996; 9: 273290.
  • 31
    Mannucci PM, Gdovin S, Gringeri A et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994; 120: 17.
  • 32
    Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39: 228230.
  • 33
    Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 25152521.
  • 34
    Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53: 450455.
  • 35
    Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005; 105: 3382.
  • 36
    Letsky EA. Haemostasis and epidural anaesthesia. Int J Obstet Anesth 1991; 1: 5154.
  • 37
    Abramovitz S, Beilin Y. Thrombocytopenia, low molecular weight heparin, and obstetric anesthesia. Anesthesiol Clin North America 2003; 21: 99109.
  • 38
    Dhar P, Abramovitz S, DiMichele D, Gibb CB, Gadalla F. Management of pregnancy in a patient with severe haemophilia A. Br J Anaesth 2003; 91: 432435.
  • 39
    Kulkarni R, Lusher JM, Henry RC, Kallen DJ. Current practices regarding newborn intracranial haemorrhage and obstetrical care and mode of delivery of pregnant haemophilia carriers: a survey of obstetricians, neonatologists and haematologists in the United States, on behalf of the National Hemophilia Foundation's Medical and Scientific Advisory Council. Haemophilia 1999; 5: 410415.
  • 40
    Ljung R, Lindgren AC, Petrini P, Tengborn L. Normal vaginal delivery is to be recommended for haemophilia carrier gravidae. Acta Paediatr 1994; 83: 609611.
  • 41
    El-Refaey H, Rodeck C. Postpartum haemorrhage: definitions, medical and surgical management. A time for change. Br Med Bull 2003; 67: 205217.
  • 42
    Hoveyda F, MacKenzie IZ. Secondary postpartum haemorrhage: incidence, morbidity, and current management. BJOG 2001; 108: 927930.
  • 43
    Mauser Bunschoten EP, Van Houwelingen JC, Sjamsoedin Visser EJ, Van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59: 349352.
  • 44
    Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labour. Cochrane Database Syst Rev 2000; CD000007.
  • 45
    Kulkarni R, Lusher JM. Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol 1999; 21: 289295.
  • 46
    Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol 2001; 112: 264274.
  • 47
    Chalmers EA, Williams MD, Richards M et al. Management of neonates with inherited bleeding disorders – a survey of current UK practice. Haemophilia 2005; 11: 186187.
  • 48
    Buchanan GR. Factor concentrate prophylaxis for neonates with hemophilia. J Pediatr Hematol Oncol 1999; 21: 254256.
  • 49
    Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600603.
  • 50
    Van Der Bom JG, Mauser-Bunschoten EP, Fischer K, Van Den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475479.
  • 51
    Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454459.
  • 52
    Miller CH. Genetics of hemophilia and von Willebrand's disease. In: HilgartnerMW, ed. Hemophilia in the Child and Adult. New York: Masson, 1982: 2962.
  • 53
    Punnonen R, Nyman D, Gronroos M, Wallen O. Von Willebrand's disease and pregnancy. Acta Obstet Gynecol Scand 1981; 60: 507509.
  • 54
    Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105: 314321.
  • 55
    Hanna W, McCarroll D, McDonald T et al. Variant von Willebrand's disease and pregnancy. Blood 1981; 58: 873879.
  • 56
    Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68: 282285.
  • 57
    Adashi EY. Lack of improvement in von Willebrand's disease during pregnancy. N Engl J Med 1980; 303: 1178.
  • 58
    Ramsahoye BH, Davies SV, Dasani H, Pearson JF. Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1: 140144.
  • 59
    Kujovich JL. von Willebrand disease and pregnancy. J Thromb Haemost 2005; 3: 246253.
  • 60
    Rick ME, Williams SB, Sacher RA, McKeown LP. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand's disease. Blood 1987; 69: 786789.
  • 61
    Caliezi C, Tsakiris DA, Behringer H, Kuhne T, Marbet GA. Two consecutive pregnancies and deliveries in a patient with von Willebrand's disease type 3. Haemophilia 1998; 4: 845849.
  • 62
    Foster PA. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 784790.
  • 63
    Steer C, Campbell S, Davies M, Mason B, Collins W. Spontaneous abortion rates after natural and assisted conception. Br Med J 1989; 299: 13171318.
  • 64
    Castaman G, Eikenboom JC, Contri A, Rodeghiero F. Pregnancy in women with type 1 von Willebrand disease caused by heterozygosity for von Willebrand factor mutation C1130F. Thromb Haemost 2000; 84: 351352.
  • 65
    Ito M, Yoshimura K, Toyoda N, Wada H. Pregnancy and delivery in patients with von Willebrand's disease. J Obstet Gynaecol Res 1997; 23: 3743.
  • 66
    Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001; 7: 235241.
  • 67
    Pasi KJ, Collins PW, Keeling DM et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 2004; 10: 218231.
  • 68
    Walker ID, Walker JJ, Colvin BT, Letsky EA, Rivers R, Stevens R. Investigation and management of haemorrhagic disorders in pregnancy. Haemostasis and Thrombosis Task Force. J Clin Pathol 1994; 47: 100108.
  • 69
    Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E. Platelet aggregation induced by 1-desamino-8-d-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med 1983; 309: 816821.
  • 70
    Dennis MW, Clough V, Toh CH. Unexpected presentation of type 2N von Willebrand disease in pregnancy. Haemophilia 2000; 6: 696697.
  • 71
    Walzman M, Bonnar J. Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. Arch Toxicol Suppl 1982; 5: 214220.
  • 72
    Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993; 70: 238240.
  • 73
    Svanberg L, Astedt B, Nilsson IM. Abruptio placentae–treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynecol Scand 1980; 59: 127130.
  • 74
    Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol 2004; 112: 154157.
  • 75
    Jones BP, Bell EA, Maroof M. Epidural labor analgesia in a parturient with von Willebrand's disease type IIA and severe preeclampsia. Anesthesiology 1999; 90: 12191220.
  • 76
    Milaskiewicz RM, Holdcroft A, Letsky E. Epidural anaesthesia and von Willebrand's disease. Anaesthesia 1990; 45: 462464.
  • 77
    Cohen S, Daitch JS, Amar D, Goldiner PL. Epidural analgesia for labor and delivery in a patient with von Willebrand's disease. Reg Anesth 1989; 14: 9597.
  • 78
    Roque H, Funai E, Lockwood CJ. von Willebrand disease and pregnancy. J Matern Fetal Med 2000; 9: 257266.
  • 79
    Kulkarni A, Riddell A, Lee CA, Kadir RA. Assessment of Factor VIII and von Willebrand Factor Levels in Cord Blood. RCOG 6th International Scientific Meeting, Cairo, Egypt, 2005.
  • 80
    Rapaport SI, Proctor RR, Patch MJ, Yettra M. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 1961; 18: 149165.
  • 81
    Leiba H, Ramot B, Many A. Heredity and coagulation studies in ten families with Factor XI (plasma thromboplastin antecedent) deficiency. Br J Haematol 1965; 11: 654665.
  • 82
    Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, Slack J, Kernoff PB. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69: 521528.
  • 83
    Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds–a clinical and laboratory study. Thromb Haemost 1995; 73: 194202.
  • 84
    Ragni MV, Sinha D, Seaman F, Lewis JH, Spero JA, Walsh PN. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood 1985; 65: 719724.
  • 85
    Salomon O, Steinberg DM, Tamarin I, Zivelin A, Seligsohn U. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16: 3741.
  • 86
    Bolton-Maggs PH. The management of factor XI deficiency. Haemophilia 1998; 4: 683688.
  • 87
    Condie RG. A serial study of coagulation factors XII, XI and X in plasma in normal pregnancy and in pregnancy complicated by pre-eclampsia. Br J Obstet Gynaecol 1976; 83: 636639.
  • 88
    Hilgartner MW, Smith CH. Plasma thromboplastin antecedent (Factor XI) in the neonate. J Pediatr 1965; 66: 747752.
  • 89
    Nossel HL, Lanzkowsky P, Levy S, Mibashan RS, Hansen JD. A study of coagulation factor levels in women during labour and in their newborn infants. Thromb Diath Haemorrh 1966; 16: 185197.
  • 90
    Mannucci PM, Bauer KA, Santagostino E et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84: 13141319.
  • 91
    Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344: 748749.
  • 92
    Billon S, Le Niger C, Escoffre-Barbe M, Vicariot M, Abgrall JF. The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001; 12: 551553.
  • 93
    O'Connell NM. Factor XI deficiency–from molecular genetics to clinical management. Blood Coagul Fibrinolysis 2003; 14(Suppl. 1): S59S64.
  • 94
    Bern MM, Sahud M, Zhukov O, Qu K, Mitchell W Jr. Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia 2005; 11: 2025.
  • 95
    Brown SA. What dose of recombinant activated factor VII should be used in patients with factor XI deficiency? Haemophilia 2005; 11: 430431.
  • 96
    Bolton-Maggs PH, Perry DJ, Chalmers EA et al. The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 2004; 10: 593628.
  • 97
    David AL, Paterson-Brown S, Letsky EA. Factor XI deficiency presenting in pregnancy: diagnosis and management. BJOG 2002; 109: 840843.
  • 98
    Bolton-Maggs PH, Wensley RT, Kernoff PB et al. Production and therapeutic use of a factor XI concentrate from plasma. Thromb Haemost 1992; 67: 314319.
  • 99
    Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002; 8: 308321.
  • 100
    Oehler MK, Rees MC. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003; 82: 405422.
  • 101
    Royal College of Obstetricians and Gynaecologists. The Initial Management of Menorrhagia – National Evidence-based Clinical Guidelines. London: RCOG Press, 1998.
  • 102
    Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss – a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45: 320351.
  • 103
    Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734739.
  • 104
    Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG 2000; 107: 320322.
  • 105
    Rees MC. Role of menstrual blood loss measurements in management of complaints of excessive menstrual bleeding. Br J Obstet Gynaecol 1991; 98: 327328.
  • 106
    Royal College of Obstetricians and Gynaecologists. The Management of Menorrhagia in Secondary Care – National Evidence-based Clinical Guidelines. London: RCOG Press, 1999.
  • 107
    Warner P, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray G. Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management. Br Med J 2001; 323: 2428.
  • 108
    Rees M. Menorrhagia. Br Med J (Clin Res Ed) 1987; 294: 759762.
  • 109
    Clarke A, Black N, Rowe P, Mott S, Howle K. Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynaecol 1995; 102: 611620.
  • 110
    Chi C, Shiltagh N, Kingman CEC, Economides DL, Lee CA, Kadir RA. Identification and mangement of women with inherited bleeding disorder: A survey of obstetrician and gynaecologists in the United Kingdom. Haemophilia 2006; 12: 405412.
  • 111
    Dilley A, Drews C, Lally C, Austin H, Barnhart E, Evatt B. A survey of gynecologists concerning menorrhagia: perceptions of bleeding disorders as a possible cause. J Womens Health Gend Based Med 2002; 11: 3944.
  • 112
    Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893898.
  • 113
    Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. Willebrand disease in women with menorrhagia: a systematic review. BJOG 2004; 111: 734740.
  • 114
    Dilley A, Drews C, Miller C et al. Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97: 630636.
  • 115
    Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485489.
  • 116
    Edlund M, Blomback M, Von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 234238.
  • 117
    Philipp CS, Dilley A, Miller CH et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1: 477484.
  • 118
    Neinstein LS. Menstrual problems in adolescents. Med Clin North Am 1990; 74: 11811203.
  • 119
    Caufriez A. Menstrual disorders in adolescence: pathophysiology and treatment. Horm Res 1991; 36: 156159.
  • 120
    Falcone T, Desjardins C, Bourque J, Granger L, Hemmings R, Quiros E. Dysfunctional uterine bleeding in adolescents. J Reprod Med 1994; 39: 761764.
  • 121
    Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP. Bleeding disorders: a common cause of menorrhagia in adolescents. J Pediatr 2001; 138: 856861.
  • 122
    Kadir RA, Lee CA. Menorrhagia in adolescents. Pediatr Ann 2001; 30: 541546.
  • 123
    Oral E, Cagdas A, Gezer A, Kaleli S, Aydin Y, Ocer F. Hematological abnormalities in adolescent menorrhagia. Arch Gynecol Obstet 2002; 266: 7274.
  • 124
    Jayasinghe Y, Moore P, Donath S, Campbell J, Monagle P, Grover S. Bleeding disorders in teenagers presenting with menorrhagia. Aust N Z J Obstet Gynaecol 2005; 45: 439443.
  • 125
    Claessens EA, Cowell CA. Acute adolescent menorrhagia. Am J Obstet Gynecol 1981; 139: 277280.
  • 126
    Smith YR, Quint EH, Hertzberg RB. Menorrhagia in adolescents requiring hospitalization. J Pediatr Adolesc Gynecol 1998; 11: 1315.
  • 127
    Philipp CS, Faiz A, Dowling N et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol 2005; 105: 6166.
  • 128
    Conlan MG, Folsom AR, Finch A et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 380385.
  • 129
    Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999; 82: 14561461.
  • 130
    Kouides PA, Conard J, Peyvandi F, Lukes A, Kadir R. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertil Steril 2005; 84: 13451351.
  • 131
    Kadir RA, Lukes AS, Kouides PA, Fernandez H, Goudemand J. Management of excessive menstrual bleeding in women with hemostatic disorders. Fertil Steril 2005; 84: 13521359.
  • 132
    Fricke W, Kouides P, Kessler C et al. A multicenter clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2004; 2: 763768.
  • 133
    Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 12431252.
  • 134
    Federici AB. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica 2003; 88: EREP02.
  • 135
    Laffan M, Brown SA, Collins PW et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 2004; 10: 199217.
  • 136
    Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160174.
  • 137
    Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: variability versus ‘variants’. Blood 1980; 56: 712716.
  • 138
    Blomback M, Eneroth P, Andersson O, Anvret M. On laboratory problems in diagnosing mild von Willebrand's disease. Am J Hematol 1992; 40: 117120.
  • 139
    Mandalaki T, Louizou C, Dimitriadou C, Symeonidis P. Variations in factor VIII during the menstrual cycle in normal women. N Engl J Med 1980; 302: 10931094.
  • 140
    Kouides P, Phatak P, Sham RL et al. Adjusting the reference range of von Willebrand factor levels and factor VIII:C levels in relation to the menstrual cycle. Blood 1997; 90: 32a.
  • 141
    Onundarson PT, Gudmundsdottir BR, Arnfinnsdottir AV, Kjeld M, Olafsson O. Von Willebrand factor does not vary during normal menstrual cycle. Thromb Haemost 2001; 85: 183184.
  • 142
    Miller CH, Dilley AB, Drews C, Richardson L, Evatt B. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost 2002; 87: 10821083.
  • 143
    Alperin JB. Estrogens and surgery in women with von Willebrand's disease. Am J Med 1982; 73: 367371.
  • 144
    Mangal AK, Naiman SC. Oral contraceptives and von Willebrand's disease. Can Med Assoc J 1983; 128: 1274.
  • 145
    Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet Gynecol Surv 1985; 40: 425436.
  • 146
    Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 16911695.
  • 147
    Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease – a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 259264.
  • 148
    Philipp CS, Miller CH, Faiz A et al. Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. Haemophilia 2005; 11: 497503.
  • 149
    Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90: 483490.
  • 150
    Quiroga T, Goycoolea M, Munoz B et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004; 2: 892898.
  • 151
    Scott JC, Mussey E. Menstrual patterns in myxoedema. Am J Obstet Gynecol 1964; 90: 161165.
  • 152
    Wilansky DL, Greisman B. Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol 1989; 160: 673677.
  • 153
    Blum M, Blum G. The possible relationship between menorrhagia and occult hypothyroidism in IUD-wearing women. Adv Contracept 1992; 8: 313317.
  • 154
    Kadir RA, Economides DL, Sabin CA, Pollard D, Lee CA. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia 1999; 5: 4048.
  • 155
    Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia 1999; 5: 313317.
  • 156
    Hayward CP. Inherited platelet disorders. Curr Opin Hematol 2003; 10: 362368.
  • 157
    James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia 2005; 11: 295307.
  • 158
    Kadir RA, Sabin CA, Pollard D, Lee CA, Economides DL. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia 1998; 4: 836841.
  • 159
    Kristjansdottir J, Johansson ED, Ruusuvaara L. The cost of the menstrual cycle in young Swedish women. Eur J Contracept Reprod Health Care 2000; 5: 152156.
  • 160
    Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia 2004; 10: 158161.
  • 161
    Khan A, Pollard D, Lee CA, Kadir RA. A first year clinical review of the multidisciplinary haemophilia/obstetrics and gynaecology clinic at the Royal Free Hospital Haemophilia Centre. Haemophilia 2004; 10(Suppl. 3): 143145.
  • 162
    Kouides PA, Phatak PD, Burkart P et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia 2000; 6: 643648.
  • 163
    Dockeray CJ, Sheppard BL, Daly L, Bonnar J. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol 1987; 24: 309318.
  • 164
    Gleeson NC. Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia. Am J Obstet Gynecol 1994; 171: 178183.
  • 165
    Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003; 63: 14171433.
  • 166
    Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994; 73: 274277.
  • 167
    Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J 1970; 4: 214216.
  • 168
    Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879883.
  • 169
    Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995; 102: 401406.
  • 170
    Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Br Med J 1996; 313: 579582.
  • 171
    Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; CD000249.
  • 172
    Rybo G. Tranexamic acid therapy: effective treatment in heavy menstrual bleeding: clinical update on safety. Therapeutic Adv 1991; 4: 18.
  • 173
    British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2004.
  • 174
    Ong YL, Hull DR, Mayne EE. Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. Haemophilia 1998; 4: 6365.
  • 175
    Callard GV, Litofsky FS, DeMerre LJ. Menstruation in women with normal or artificially controlled cycles. Fertil Steril 1966; 17: 684688.
  • 176
    Ramcharan S, Pellegrin FA, Ray RM, Hsu JP. The Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives. Volume III, an interim report: a comparison of disease occurrence leading to hospitalization or death in users and nonusers of oral contraceptives. J Reprod Med 1980; 25: 345372.
  • 177
    Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971; 110: 713720.
  • 178
    Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991; 31: 6670.
  • 179
    Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 5261.
  • 180
    Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179183.
  • 181
    Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261266.
  • 182
    Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003; 67: 913.
  • 183
    Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98: 771778.
  • 184
    Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101: 653661.
  • 185
    Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; CD004695.
  • 186
    Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58: 10331036.
  • 187
    Cash JD, Gader AM, Da Costa J. Proceedings: the release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 1974; 27: 363364.
  • 188
    Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 8193.
  • 189
    Sakariassen KS, Cattaneo M, Vd Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64: 229236.
  • 190
    Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 1981; 47: 283293.
  • 191
    Mannucci PM, Vicente V, Alberca I et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987; 58: 10371039.
  • 192
    Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114: 563568.
  • 193
    Lethagen S, Ragnarson TG. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993; 66: 257260.
  • 194
    Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I. Blut 1990; 60: 187191.
  • 195
    Edlund M, Blomback M, He S. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagul Fibrinolysis 2003; 14: 593598.
  • 196
    Bonnar J, Sheppard BL, Dockeray CJ. The haemostatic system and dysfunctional uterine bleeding. Res Clin Forum 1983; 5: 2736.
  • 197
    Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 692696.
  • 198
    Leissinger C, Becton D, Cornell C Jr, Cox GJ. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7: 258266.
  • 199
    Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002; 8: 787793.
  • 200
    Edlund M, Blomback M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis 2002; 13: 225231.
  • 201
    Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85: 977982.
  • 202
    Coulter A, Kelland J, Peto V, Rees MC. Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 1995; 11: 456471.
  • 203
    Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; CD001016.
  • 204
    Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105: 592598.
  • 205
    Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; CD000400.
  • 206
    Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986; 5: 235241.
  • 207
    Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG 2001; 108: 7486.
  • 208
    Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; CD002126.
  • 209
    Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 2005; 112: 11211125.
  • 210
    Lahteenmaki P, Haukkamaa M, Puolakka J et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. Br Med J 1998; 316: 11221126.
  • 211
    Hurskainen R, Teperi J, Rissanen P et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273277.
  • 212
    Hurskainen R, Teperi J, Rissanen P et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004; 291: 14561463.
  • 213
    Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65: 129132.
  • 214
    Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49: 5672.
  • 215
    Sivin I, El Mahgoub S, McCarthy T et al. Long-term contraception with the levonorgestrel 20 mcg day−1 (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception 1990; 42: 361378.
  • 216
    Nagrani R, Bowen-Simpkins P, Barrington JW. Can the levonorgestrel intrauterine system replace surgical treatment for the management of menorrhagia? BJOG 2002; 109: 345347.
  • 217
    Xiao B, Wu SC, Chong J, Zeng T, Han LH, Luukkainen T. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril 2003; 79: 963969.
  • 218
    Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004; 111: 14251428.
  • 219
    Lukes AS, Kouides PA. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol 2004; 104: 864865.
  • 220
    Maresh MJ, Metcalfe MA, McPherson K et al. The VALUE national hysterectomy study: description of the patients and their surgery. BJOG 2002; 109: 302312.
  • 221
    McPherson K, Metcalfe MA, Herbert A et al. Severe complications of hysterectomy: the VALUE study. BJOG 2004; 111: 688694.
  • 222
    Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; CD000329.
  • 223
    Lethaby A, Hickey M. Endometrial destruction techniques for heavy menstrual bleeding: a Cochrane review. Hum Reprod 2002; 17: 27952806.
  • 224
    Toth D, Gervaise A, Kuzel D, Fernandez H. Thermal balloon ablation in patients with multiple morbidity: 3-year follow-up. J Am Assoc Gynecol Laparosc 2004; 11: 236239.
  • 225
    Rubin G, Wortman M, Kouides PA. Endometrial ablation for von Willebrand disease-related menorrhagia – experience with seven cases. Haemophilia 2004; 10: 477482.
  • 226
    Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973; 238: 1159.
  • 227
    Hann LE, Hall DA, Black EB, Ferrucci JT Jr. Mittelschmerz. Sonographic demonstration. JAMA 1979; 241: 27312732.
  • 228
    O'Brien PM, DiMichele DM, Walterhouse DO. Management of an acute hemorrhagic ovarian cyst in a female patient with hemophilia A. J Pediatr Hematol Oncol 1996; 18: 233236.
  • 229
    Jarvis RR, Olsen ME. Type I von Willebrand's disease presenting as recurrent corpus hemorrhagicum. Obstet Gynecol 2002; 99: 887888.
  • 230
    Mishell DR Jr. Noncontraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol 1982; 142: 809816.
  • 231
    Bottini E, Pareti FI, Mari D, Mannucci PM, Muggiasca ML, Conti M. Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and afibrinogenemia. Case reports. Haematologica 1991; 76: 431433.
  • 232
    Ghosh K, Mohanty D, Pathare AV, Jijina F. Recurrent haemoperitoneum in a female patient with type III von Willebrand's disease responded to administration of oral contraceptive. Haemophilia 1998; 4: 767768.
  • 233
    Vercellini P, De Giorgi O, Aimi G, Panazza S, Uglietti A, Crosignani PG. Menstrual characteristics in women with and without endometriosis. Obstet Gynecol 1997; 90: 264268.
  • 234
    D'Hooghe TM, Bambra CS, Raeymaekers BM, Koninckx PR. Increased prevalence and recurrence of retrograde menstruation in baboons with spontaneous endometriosis. Hum Reprod 1996; 11: 20222025.
  • 235
    Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics 1981; 68: 661664.
  • 236
    Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med 1997; 151: 905913.
  • 237
    Davis AR, Westhoff CL. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol 2001; 14: 38.
  • 238
    Banikarim C, Chacko MR, Kelder SH. Prevalence and impact of dysmenorrhea on Hispanic female adolescents. Arch Pediatr Adolesc Med 2000; 154: 12261229.
  • 239
    Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv 2000; 55: 103108.
  • 240
    Rodeghiero F, Castaman GC, Di Bona E, Ruggeri M, Dini E. Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy. Report of a second case. Blut 1987; 55: 4548.
  • 241
    Inbal A, Muszbek L. Coagulation factor deficiencies and pregnancy loss. Semin Thromb Hemost 2003; 29: 171174.
  • 242
    Kobayashi T, Kanayama N, Tokunaga N, Asahina T, Terao T. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 2000; 109: 364366.
  • 243
    Evron S, Anteby SO, Brzezinsky A, Samueloff A, Eldor A. Congenital afibrinogenemia and recurrent early abortion: a case report. Eur J Obstet Gynecol Reprod Biol 1985; 19: 307311.
  • 244
    Grech H, Majumdar G, Lawrie AS, Savidge GF. Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature. Br J Haematol 1991; 78: 571572.
  • 245
    Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. Br Med J 1997; 315: 3234.
  • 246
    Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. Br Med J 2000; 320: 17081712.
  • 247
    Wilcox AJ, Weinberg CR, O'Connor JF et al. Incidence of early loss of pregnancy. N Engl J Med 1988; 319: 189194.
  • 248
    Trehan AK, Fergusson IL. Congenital afibrinogenaemia and successful pregnancy outcome. Case report. Br J Obstet Gynaecol 1991; 98: 722724.
  • 249
    Kobayashi T, Asahina T, Maehara K, Itoh M, Kanayama N, Terao T. Congenital afibrinogenemia with successful delivery. Gynecol Obstet Invest 1996; 42: 6669.
  • 250
    Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 2003; 9: 292297.